Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leuk Res
; 28(9): 991-4, 2004 Sep.
Article
em En
| MEDLINE
| ID: mdl-15234578
ABSTRACT
Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Leucemia Promielocítica Aguda
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Infiltração Leucêmica
Tipo de estudo:
Etiology_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2004
Tipo de documento:
Article